RELYVRIO Drug Patent Profile

When do Relyvrio patents expire, and what generic alternatives are available?

Relyvrio is a drug marketed by Amylyx and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-five patent family members in twenty-five countries.

The generic ingredient in RELYVRIO is sodium phenylbutyrate; taurursodiol. There are one thousand four hundred and seventy-two drug master file entries for this compound. Additional details are available on the sodium phenylbutyrate; taurursodiol profile page.

DrugPatentWatch^® Generic Entry Outlook for Relyvrio

Relyvrio will be eligible for patent challenges on September 29, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 29, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for RELYVRIO

International Patents:	65
US Patents:	5
Applicants:	1
NDAs:	1
Clinical Trials:	2
Drug Prices:	Drug price information for RELYVRIO
What excipients (inactive ingredients) are in RELYVRIO?	RELYVRIO excipients list
DailyMed Link:	RELYVRIO at DailyMed

See drug prices for RELYVRIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RELYVRIO

Constraining patent/regulatory exclusivity:

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS

NDA:

216660

Dosage:

FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RELYVRIO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Université de Montréal	PHASE2
Oliver Blanchard	PHASE2
Amylyx Pharmaceuticals Inc.	Phase 3

See all RELYVRIO clinical trials

US Patents and Regulatory Information for RELYVRIO

RELYVRIO is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amylyx	RELYVRIO	sodium phenylbutyrate; taurursodiol	FOR SUSPENSION;ORAL	216660-001	Sep 29, 2022		DISCN	Yes	No
Amylyx	RELYVRIO	sodium phenylbutyrate; taurursodiol	FOR SUSPENSION;ORAL	216660-001	Sep 29, 2022		DISCN	Yes	No
Amylyx	RELYVRIO	sodium phenylbutyrate; taurursodiol	FOR SUSPENSION;ORAL	216660-001	Sep 29, 2022		DISCN	Yes	No			Y

International Patents for RELYVRIO

See the table below for patents covering RELYVRIO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014242123
Australia	2019200658
Australia	2021201770

Supplementary Protection Certificates for RELYVRIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0957929	06C0021	France		PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0788511	SPC/GB08/036	United Kingdom		PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
1713823	1490064-1	Sweden		PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516

Relyvrio (ambranemab/tafamidis? actually ambranemab + tauroursodeoxycholic acid) market dynamics and financial trajectory: sales trends, pricing, exclusivity, and generic risk

Last updated: July 23, 2026

Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) is a US ALS therapy whose commercial trajectory has tightened around payer access, high list-price pressure, and limited durable volume growth since launch. Market dynamics are dominated by (1) post-launch prescribing shifts driven by safety/tolerability and real-world use patterns, (2) reimbursement coverage constraints tied to budget impact, and (3) the competitive overhang from other ALS agents and pipeline “next-wave” trials, which compress patient lifetime value and increase scrutiny of value evidence.

Key financial takeaways are that Relyvrio’s revenue run rate has not scaled to offset cost of goods and launch-era SG&A, leading to shareholder-level repositioning by Amylyx and persistent cash burn. The central IP and regulatory risk for competitors is medium-to-high near-term because Relyvrio’s exclusivity and patent stack does not block all generics in every jurisdiction and dosage/manufacturing variation; however, US generic entry has been gated by the pace and outcomes of patent litigation and any Orange Book landscape-specific challenges.

---

How has Relyvrio performed commercially since launch and what drives month-to-month revenue?

Answer: Commercial performance is mainly shaped by payer coverage breadth, dose adherence economics, and prescriber adoption constraints in ALS. Relyvrio’s sales have tracked slower-than-expected scaling after initial launch lift, with later periods constrained by reimbursement friction and increased competition for limited ALS specialist attention.

What market dynamics determine Relyvrio uptake

• Coverage and formulary placement: ALS is high-cost, chronic therapy with narrow insurer appetite unless supported by strong outcomes evidence. In practice, coverage tends to be conditional on prior authorization and specialty pharmacy routing, which delays and dampens conversion from trial to real-world.
• Net price compression from rebates: High list pricing with reimbursement friction usually produces meaningful net price reductions versus headline price, especially when payers require outcomes justification.
• Real-world tolerability and persistence: Sodium phenylbutyrate and taurursodiol regimens can create side-effect burdens (GI events) that reduce adherence and shorten treatment duration for some patients.
• Prescriber behavior: ALS neurologists weigh evidence strength versus safety and compare against alternative disease-modifying options and supportive care strategies.

Revenue mechanics that matter to finance teams

For revenue modeling, the dominant drivers are:

• Patients treated (incidence-to-treated conversion)
• Average daily dose utilization and treatment duration
• Average net price (after rebates, patient assistance, and payer-specific discounts)
• Channel execution through specialty pharmacies

---

What is the financial trajectory for Amylyx after Relyvrio revenue, cost structure, and cash burn?

Answer: The post-launch period has been characterized by low-to-modest revenue scale relative to fixed operating costs and ongoing R&D and regulatory expenses. This mix drives negative operating cash flow and forces management to prioritize portfolio survival actions.

Why Relyvrio revenue did not reach “scale threshold”

• High fixed cost base: Manufacturing, quality, pharmacovigilance, and US commercialization costs do not fall proportionally with small patient numbers.
• Value narrative under payer review: Payers often require robust evidence of net benefit; where uncertainty persists, treatment volume tends to plateau.
• Portfolio concentration risk: When a company’s top-line depends heavily on one product, any coverage setbacks quickly propagate into financial projections.

Common investor and lender focus points

• Gross-to-net erosion trajectory.
• Operating expense controls (headcount, clinical spend, commercialization).
• Cash runway and financing actions.
• Probability-weighted future milestones tied to additional assets.

---

What patents protect Relyvrio in the US and how strong is the patent estate for generic defense?

Answer: Relyvrio’s US exclusivity and patent protection depend on compound, formulation, method-of-use, and process claims, plus any Orange Book listing coverage that maps to the marketed formulation. The strength is heterogeneous by claim type and by the ability of challengers to design around manufacturing steps.

How to assess “strength” for Relyvrio

Patent defense strength typically depends on:

• Claim scope of active-ingredient composition and salt/crystal forms (if applicable).
• Formulation-specific exclusivity for the marketed dosage form.
• Method-of-use claim coverage for ALS populations, treatment schedules, or endpoints.
• Process patents that can be harder to design around without significant reformulation risk.

---

When does Relyvrio lose exclusivity in the US and what are the key timeline risk points?

Answer: Generic risk rises at key exclusivity expiration and at each litigation settlement or final judgment stage. Even if compound exclusivity holds, formulary access can shift earlier if challengers gain leverage through design-around or non-ANDA pathways.

Exclusivity timeline framework

To forecast entry timing, teams usually map:

• Orange Book exclusivity (NCE or new formulation exclusivity where applicable)
• Patent expiration dates by listing (composition, method-of-use, formulation/process)
• Regulatory and litigation milestones that affect whether an ANDA can be filed or approved.

---

Has any generic or biosimilar risk emerged for Relyvrio via ANDA filings or Paragraph IV challenges?

Answer: Relyvrio faces US generic risk through ANDA pathways if Orange Book-protected patents are challenged (Paragraph IV) or circumvented via non-infringing formulations/manufacturing changes. The practical risk level depends on the state of litigation and court outcomes tied to Orange Book listings.

What to track in dispute filings

• Whether challengers assert non-infringement or invalidity.
• Whether courts issue preliminary injunctions.
• Settlement terms such as “no entry until” dates, partial licensing, or launch carve-outs.

---

What is the Orange Book status of Relyvrio and which listed patents drive market protection?

Answer: The Orange Book listing set is the key gating layer for US market protection. For Relyvrio, the listed patents that matter for generic entry are those with scopes that cover the marketed product and that remain enforceable at the time of ANDA approval.

Operational approach for licensing and litigation teams

• Build a patent-to-product claim chart covering:
  • marketed drug substance
  • marketed drug product formulation
  • method-of-use indications
  • manufacturing/process steps used in commercial supply
• Identify which listed patents are most likely to be:
  • asserted successfully
  • struck as invalid
  • designed around by a challenger.

---

How does Relyvrio compare with other ALS therapies on payer access and competitive positioning?

Answer: Competitive pressure comes from broader ALS treatment options and supportive care pathways that can crowd out newer or higher-uncertainty value propositions. Relyvrio’s payer traction is sensitive to outcome evidence and formulary leverage across regional and PBM-managed networks.

Competitive comparables that influence payer and clinician choices

• Disease-modifying therapies in ALS (including agents with different dosing and evidence profiles).
• Non-disease-modifying interventions that can still win share through ease of reimbursement or better tolerability.

Implication for market share

When alternative therapies have clearer value evidence or easier coverage, Relyvrio’s incremental uptake is slower and discontinuation risk can rise.

---

What settlement or licensing terms have shaped Relyvrio’s competitive landscape?

Answer: Market access and launch timing outcomes for generics are often driven by settlement terms that define “entry windows,” partial carve-outs, and sometimes supply or distribution commitments. Whether Relyvrio’s competitive landscape is improving for generics depends on the existence and terms of any such agreements tied to Orange Book patents.

---

What manufacturing and formulation barriers could slow generic entry for Relyvrio?

Answer: Generic entry speed for complex regimens is often constrained by manufacturing equivalence, stability, and patient-friendly administration requirements. Even when patents expire, practical time-to-market can remain lengthy.

Key barriers to evaluate

• Stability and bioequivalence requirements for specific formulations.
• Supply chain capacity and batch consistency for commercial-scale manufacturing.
• Ability to source or replicate key intermediates.
• Scale-up validation timelines and quality system readiness.

---

What regulatory milestones affect Relyvrio’s market trajectory beyond patent expiry?

Answer: FDA label changes, REMS-like policy (if any), postmarketing requirements, and safety signal resolution can shift prescribing and payer coverage even without formal exclusivity loss.

Regulatory factors that can move the curve

• Label expansions or clarifications that increase treatable populations.
• Safety updates that reduce clinician willingness in certain subgroups.
• Postmarketing study outcomes that influence payer confidence.

---

How much revenue exposure does Relyvrio represent and what do investors model for downside and upside?

Answer: Relyvrio’s revenue exposure is high for a small commercial-stage company and is typically modeled as the near-term revenue base under a probability-weighted pipeline plan. Upside requires faster-than-expected net price stabilization and sustained volume growth; downside reflects payer tightening, higher discontinuation, and delayed or unsuccessful portfolio execution.

Modeling frame used by buy-side teams

• Base-case: steady patient treated and net price erosion within historical bands.
• Downside: stronger payer restriction and lower persistence.
• Upside: expanded coverage or improved real-world evidence translating into formulary reinstatement.

---

Key Takeaways

• Relyvrio’s market dynamics are dominated by payer coverage execution, net pricing pressure, and real-world persistence constraints in ALS.
• The financial trajectory since launch has been constrained by sales scale not matching the operating cost base, driving continued cash strain for the company behind the product.
• Generic risk exists through ANDA routes tied to Orange Book listings, but actual entry timing depends on patent validity/infringement outcomes and any settlements.
• Competitively, Relyvrio faces continuing ALS therapeutic crowding that compresses share growth and can increase discontinuation sensitivity.

---

FAQs

1) What net price erosion has Relyvrio faced in US payer contracts?
Net price erosion typically reflects rebate pressure, prior authorization friction, and specialty pharmacy reimbursement mechanics that reduce realized revenue versus list price.

2) What evidence endpoints matter most to payers for Relyvrio coverage decisions?
Payers focus on durability of clinical benefit, tolerability in routine care, and the strength of outcome signals relative to cost and comparator therapies.

3) How do settlement agreements typically influence Relyvrio generic launch timing?
Settlements usually establish “no entry” dates tied to patent expiration or define partial carve-outs that limit immediate launch or restrict distribution timing.

4) What manufacturing equivalence issues can delay generic Relyvrio even if patents expire?
Formulation stability, bioequivalence demonstration, and commercial batch consistency can create practical delays beyond formal exclusivity expiration.

5) How does Relyvrio’s ALS competition affect prescribing patterns in specialty clinics?
Competition shifts clinician preferences based on perceived benefit-risk, ease of reimbursement, and how quickly new data changes treatment protocols in ALS centers.

---

References

No sources were provided in the prompt, and no verifiable Orange Book, litigation docket, or audited financial filings were included.

DrugChatter Q&A for RELYVRIO

Can relyvrio be used for als?
How does Relyvrio treat ALS symptoms?
How does the drug Relyvrio work for ALS?